Clinical trials: Mental Depression
Treatment Resistant Depression
Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)
The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant…
- Trial name
- NCT04663321
- Testing
- MK-1942
- Where
- 45 sites in United States
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Anxiety, Self-Efficacy
Musically-Guided Paced Breathing Improves Mental Health in War-Affected Adolescents
Examine the impact of a mindfulness condition, a guided paced breathing audiovisual intervention condition, and a guided paced breathing audiovisual intervention plus take-home application condition compared to a matched control…
- Conditions
- Anxiety, Self-Efficacy, Depression Not Otherwise Specified
- Trial name
- NCT06988800
- Testing
- Paced breathing wellness breathing sessions, Mindfulness video sessions
- Where
- Palestinian Territories
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Muvik Labs
Major Depressive Disorder (MDD)
A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects
The two products used in this study are transdermal patches that contain selegiline. The test drug is the Selegiline Transdermal Delivery System (TDS). The comparator drug is the EMSAM® TDS.
- Trial name
- NCT07452692
- Testing
- Selegiline Transdermal Delivery System
- Where
- 3 sites in Bulgaria
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Corium Innovations, Inc.
Major Depressive Disorder
A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of two fixed doses of vortioxetine (Lu AA21004; 10 or 20 mg/day) after 8 weeks of treatment in patients with major depressive disorder (MDD) in Japan.
- Trial name
- NCT02389816
- Testing
- Vortioxetine
- Where
- 47 sites in Japan
- Volunteers
- 493 people
- Sponsor
- Takeda
Bipolar Disorder, Major Depressive Disorder
Clinical Validation Study for EDIT-B Test: an Aid for Differential Diagnosis of Bipolar Disorder, Based on RNA Editing Blood Biomarkers
Differentiation between major depressive disorder (MDD) and bipolar disorder (BD) as soon as possible in the patient journey represents a major clinical issue.
- Trial name
- EDIT-B (NCT05603819)
- Testing
- EDIT-B
- Where
- 4 sites in Denmark, France and 1 more
- Volunteers
- 418 people
- Sponsor
- Alcediag
Major Depressive Disorder
A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD.
- Trial name
- NCT00644358
- Testing
- vilazodone
- Where
- 38 sites in United States
- Volunteers
- 616 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Major
The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use
The primary objective of this study is to measure the effects of patient cost-sharing on the initiation of adjunctive treatment and subsequent healthcare utilization and expenditures among a population of commercially insured…
- Trial name
- NCT01141400
- Volunteers
- 48,865 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, Insomnia
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia
This study is a randomized, double-blind, placebo-controlled study of the safety, tolerability, and efficacy of SAGE-217 compared to placebo in adult participants with comorbid major depressive disorder (MDD) and insomnia.
- Trial name
- NCT03771664
- Testing
- SAGE-217
- Where
- 28 sites in United States
- Volunteers
- 87 people
- Sponsor
- Biogen
Major Depressive Disorder
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)
This is a Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult participants with MDD.
- Trial name
- NCT03864614
- Testing
- SAGE-217
- Where
- 52 sites in United States
- Volunteers
- 1,515 people
- Sponsor
- Biogen
Depression, Anxiety
Potency and Precision Investigation
The overarching goal of this study is to establish initial proof of mechanism for precision interventions in an adult population.
- Trial name
- PAPI (NCT06240091)
- Testing
- DISC-MA
- Where
- United States
- Volunteers
- 203 people
- Sponsor
- Woebot Health
Major Depressive Disorder
A Study of LY2216684 in Healthy Participants
This study will evaluate the pharmacodynamic and pharmacokinetic interaction of LY2216684 with alcohol in healthy participants. This study will run approximately for 34 days.
- Trial name
- NCT01380691
- Testing
- LY2216684, Alcoholic beverage
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
- Trial name
- DIAMOND (NCT00321490)
- Testing
- Quetiapine fumarate, Duloxetine
- Where
- 34 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00672620
- Testing
- Vortioxetine, Duloxetine
- Where
- 38 sites in United States
- Volunteers
- 611 people
- Sponsor
- Takeda
Treatment-Resistant Depression
Efficacy and Safety of TAK-653 in Treatment-Resistant Depression
The purpose of this study is to evaluate the efficacy of TAK-653 compared with placebo in maintaining the effect of ketamine treatment on depressive symptoms.
- Trial name
- NCT03312894
- Testing
- TAK-653
- Sponsor
- Millennium Pharmaceuticals, Inc.
Depressive Disorder, Major
A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in participants with Major Depressive Disorder (MDD) partially responsive to selective serotonin…
- Trial name
- NCT03559192
- Testing
- JNJ-67953964
- Where
- 53 sites in United States, Germany and 4 more
- Volunteers
- 181 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone.
- Trial name
- NCT01469377
- Testing
- Cariprazine
- Where
- 72 sites in United States, Estonia and 4 more
- Volunteers
- 819 people
- Sponsor
- Forest Laboratories
Depression, Anxiety
Effect of Two Probiotic Formulations on Mental Health and Mood Biomarkers in Adults With Depressive Symptoms
This is a 3-arm, parallel-group, randomized, double-blind, placebo-controlled pilot trial. Sixty adults presenting with depressive symptoms will be randomly allocated to one of 3 groups comprising (1) Bifidobacterium adolescentis…
- Trial name
- NCT05564767
- Testing
- B. adolescentis Bif-038, Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12®
- Where
- Australia
- Volunteers
- 62 people
- Sponsor
- Chr Hansen
Respiratory Depression, Respiratory Failure
VitalThings Guardian Contactless Monitoring
This is a confirmatory study without any intervention. It is an uncontrolled, non-randomized and open-label study with measurements made with comparators, and it has a preset hypothesis for the primary endpoint.
- Conditions
- Respiratory Depression, Respiratory Failure, Deterioration, Clinical
- Trial name
- VINCENT (NCT06083272)
- Testing
- Vitalthings Guardian M10 fixed and M10 mobile
- Where
- Norway
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- VitalThings
Contraception, Premenstrual Syndrome
Regulatory Post Marketing Surveillance Study on YAZ
The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice.
- Conditions
- Contraception, Premenstrual Syndrome, Acne
- Trial name
- NCT00998257
- Testing
- EE20/DRSP (YAZ, BAY86-5300)
- Where
- South Korea
- Volunteers
- 770 people
- Sponsor
- Bayer
Depression
Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects
The purpose of this study is to determine the effect of a single dose infusion of AZD 6765 compared with placebo and ketamine on the blood oxygen level dependent signal using fMRI (functional Magnetic Resonance Imaging) in…
- Trial name
- NCT01046630
- Testing
- AZD6765, Ketamine
- Where
- 2 sites in United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.